WHO vaccine-preventable diseases: monitoring system. 2017 global summary

Last updated 31-July-2017 (data as of 19-July-2017)
Next overall update Fall-2017
EPI mother and child logo         
Select a country

Development status: Least developed GNI / capita (US$): 8801 Infant (under 12 months) mortality rate: 852
GDP / capita (US$): 2'1711 Child (under 5 years) mortality rate: 1392

Population data in thousands3

  2016  2015  2014  2013  2012  2000  1990  1980 
Total population 14'453  14'009  13'569  13'134  12'705  8'343  5'957  4'512 
Births 627  615  603  592  580  427  304  225 
Surviving infants 575  562  550  538  526  379  267  195 
Pop. less than 5 years 2'666  2'601  2'541  2'480  2'420  1'684  1'175  856 
Pop. less than 15 years 6'848  6'666  6'494  6'317  6'137  4'075  2'827  2'033 
Female 15-49 years 3'207  3'093  2'975  2'862  2'753  1'777  1'279  1'001 

Number of reported cases

(Click for retrospective incidence data for Chad)
Diphtheria
ChartChart
 
Japanese encephalitis
 
Measles
ChartChart ChartChart
  118  418  1'275  226  120  3'546  7'226 
Mumps
ChartChart
 
Pertussis
ChartChart
 
Polio*
ChartChart
  17  60 
Rubella
ChartChart
  24  31 
Rubella (CRS)
ChartChart
 
Tetanus (neonatal)
ChartChart
  172  195  154  176  225  142  738 
Tetanus (total)**
ChartChart
  172  195  154  176  225  1'603 
Yellow fever
ChartChart
  48 
* Polio refers to all polio cases (indigenous or imported), including polio cases caused by vaccine derived polio viruses (VDPV). For disaggregated data please click on this hyperlink: https://extranet.who.int/polis/public/CaseCount.aspx
it does not include cases of vaccine-associated paralytic polio (VAPP) and cases of non polio acute flaccid paralysis [AFP]).
** Neonatal Tetanus and Total Tetanus cases equality may be the result from a lack of non-Neonatal Tetanus surveillance system.

Percentage target population vaccinated by antigen

Hovering over an antigen reveals its fuller definition
  Most recent coverage survey4  

Official country estimates5

  (Click for retrospective coverage estimates data for Chad)
Vaccine year result method % card seen                                                
BCG 2013  60  DHS/MICS   32  75  96  85  83  79  50 
DTP1 2013  58  DHS/MICS   32  90  99*  99  98  93  45 
DTP3 2013  33  DHS/MICS   32  78  92  83  80  72  28  20 
DTP4         
IPV1          75  28 
HepB_BD         
HepB3 2013  33  DHS/MICS   32  78  92  83  80  72 
Hib3 2013  33  DHS/MICS   32  78  92  83  80  72 
JapEnc         
MCV1          75  87  79  79  69  42 
MCV2         
MenA         
PCV1         
PCV2         
PCV3         
Pol3 2013  50  DHS/MICS   32  75  89  81  80  73  29  16 
Rota1         
RotaC         
RCV1         
TT2plus 2009  38  MICS   21  80  96  83  78  70  12 
PAB          83  89 
VAD1         
YFV 2013  44  DHS/MICS   32  70  84  75  79  70  36 
* indicates the country reported above 100% coverage.

  Next update: Mid-July 2018

WHO-UNICEF estimates6

  (Click for full retrospective WHO-UNICEF coverage estimates data for Chad)
BCG
ChartChart
  56  68  57  60  62  49  59 
DTP1
ChartChart
  60  60  60  58  57  45  44 
DTP3
ChartChart
  46  46  37  39  40  36  20 
HepB3
ChartChart
  46  46  37  39  40 
HepB_BD
ChartChart
 
Hib3
ChartChart
  46  46  37  39  40 
IPV1
  46  28 
MCV1
ChartChart
  58  60  52  57  63  28  32 
MCV2
 
PCV3
 
Pol3
ChartChart
  44  52  44  46  51  30  20 
RCV1
 
RotaC
 
YFV
ChartChart
  44  44  35  44  51  28 

Click for WHO-UNICEF coverage estimates data for PAB time series.

Number of districts in the country 99  Proportion of
districts reporting
DTP3 coverage:
% of coverage reports received at national
level vs number of reports expected
100 
   
/
|
|
\
Greater or equal to 90% 44
From 80 to 89% 21
From 50 to 79% 23
Less than 50% 11
Proportion of districts
not reporting DTP3 coverage
0
DTP3 reported coverageDTP3 reported coverage

Immunization Schedule (2016 or latest available)

Hovering over an antigen reveals its fuller definition
Vaccine Schedule Entire country Comment
BCG birth; Yes
DTwPHibHepB 6, 10, 14 weeks; Yes
IPV 14 weeks; Yes
Measles 9 months; Yes
OPV Birth; 6, 10, 14 weeks; Yes
TT 1st contact; +1, +6 months; +1, +1 year; Yes Pregnant women
YF 9 months; Yes

Immunizaton indicators

Indicator Expected answer 2016  2015  2014  2013  2012  2011  2010 

Planning and management

Has the country a Multi-Year Plan (MYP) for immunization? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 
What years does the MYP cover? number 2013-2017  2013-2017  2013-2017  2013-2017  2013 - 2017  2008 - 2012  2008-2012 
Nº of districts with microplans that include activities to raise immunization coverage number 99  84  77  70  61  61  37 

System performance

Total Nº districts in country number 99  84  77  70  61  61  61 
Nº districts with DTP3 coverage >=80% number 65  50  39  42  32  19  33 
% of districts with DTP3 coverage >=80% From 0 to 100% 66  60  51  60  52  31  54 
Nº districts with measles (MCV1) coverage >=95% number 26  25  17  21  24  14  20 
% of districts with MCV1 coverage >=95% From 0 to 100% 26  30  22  30  39  23  33 

Safety

Has the country a vaccine adverse events review committee? Yes/No/NR/ND Yes  Yes  Yes  Yes  Yes  No  No 
Is there a national system to monitor adverse events following immunization (AEFI)? Yes/No/NR Yes  Yes  Yes  No  No  No  No 

Finance

% of Immunization expenditure financed, using Government funds? From 0 to 100% 38  38  54  35  43  11  94 

National Immunization Advisory Mechanism

Has the country a standing technical advisory group on immunization (NITAG)? Yes/No/NR No  No  No  No  No  No   

Sources

 1  "The 2017 World Bank Development Indicators Online", GDP per capita is PPP adjusted.
 2  World Health Statistics 2016, data for 2015
 3  "United Nations, Population Division. The World Population Prospects - the 2017 revision". New York, 2017.
 4  UNICEF/WHO survey database
 5  If no official estimate is available, the administrative coverage is reported. '*' indicates coverage over 99.5%.
 6  WHO-UNICEF estimates.